Top 100 FCA Cases

Top False Claims Act Cases by Civil Award Amount

  • Cases with an asterisk (*) are cases in which criminal penalties were also assessed.
  • Cases with a diamond ( ♦ ) are state cases.
    Company Civil Fine ($)
    GlaxoSmithKline* 2,000,000,000
    Johnson & Johnson* 1,720,000,000
    Pfizer* 1,000,000,000
    Bank of America 1,000,000,000
    Tenet 900,000,000
    Abbott* 800,000,000
    HCA* 731,400,000
    Merck 650,000,000
    HCA* 631,000,000
    Merck* 628,000,000
    JPMorgan Chase 614,000,000
    Amgen* 612,000,000
    GlaxoSmithKilne* 600,000,000
    Serono Group* 567,000,000
    The Boeing Company 565,000,000
    TAP Pharmaceuticals 559,483,560
    New York State and NYC 540,000,000
    Astra Zeneca 520,000,000
    Pfizer* 491,000,000
    DaVita 450,000,000
    Schering Plough 435,000,000
    Eli Lilly 438,000,000
    Abbott Labs* 400,000,000
    DaVita 400,000,000
    Novartis 390,000,000
    Fresenius Medical Care of N. America* 385,000,000
    Cephalon 375,000,000
    United Technologies 365,000,000
    Ranbaxy* 350,000,000
    Bristol-Myers Squibb 328,000,000
    Northrop-Grumman 325,000,000
    SmithKline Beecham Clinical Labs 325,000,000
    HealthSouth* 325,000,000
    National Medical Enterprises* 324,200,000
    Gambro Healthcare 310,000,000
    Schering-Plough* 292,969,482
    Mylan 280,000,000
    Roxanne 280,000,000
    AstraZeneca* 266,127,844
    St. Barnabas Hospitals 265,000,000
    Rapamune* 257,400,000
    Bayer Corp.* 257,200,000
    Millennium Health 256,000,000
    Schering Plough 250,000,000
    Quest Diagnostics♦ 241,000,000
    First American Health Care Of Georgia (only fractional payment actually made after bankrupcy) 225,000,000
    Amerigroup 225,000,000
    First Tennessee Bank 212,500,000
    Deutsche Bank 202,000,000
    Actavis (global settlement after verdict) 202,000,000
    Oracle 200,000,000
    U.S. Bank 200,000,000
    Endo Pharmaceutical 192,500,000
    McKesson 190,000,000
    BankAmerica* 187,000,000
    Laboratory Corp. of America* 182,000,000
    Aventis Pharmaceuticals 180,000,000
    Endo Pharmaceuticals* 171,900,000
    Beverly Enterprises Inc.* 170,000,000
    Zimmer Inc. 169,500,000
    Purdue Frederick Co 160,000,000
    Citigroup 158,000,000
    Johnson & Johnson♦ (verdict) 158,000,000
    Par Pharmaceutical 154,000,000
    Pfizer/Warner-Lambert* 152,000,000
    Medco 150,000,000
    Sandoz 150,000,000
    Amedisys 150,000,000
    United Technologies 150,000,000
    Maxim 150,000,000
    GlaxoSmithKline 150,000,000
    Forest Pharmaceuticals 149,000,000
    Blue Cross Blue Shield Illinois* 140,000,000
    Wellcare 137,500,000
    Caremark 137,500,000
    Mario Gabelli et. al 130,000,000
    NetApp 128,000,000
    Kindred Healthcare Inc. 125,000,000
    Warner Chilcott* 125,000,000
    King Pharmaceutical 124,000,000
    OmniCare 124,000,000
    MetLife Home Loans LLC 123,500,000
    Adventist Health System 118,700,000
    Northrop Grumman 111,200,000
    Shell Oil Company 110,000,000
    Sanofi 109,000,000
    Vencor Inc./Ventas Inc. 104,500,000
    Supreme Foodservice GmbH. 101,000,000
    National Health Labs 100,000,000


GlaxoSmithKline plead guilty to several criminal misdemeanor charges and paid $3 billion ($2 billion civil, $1 billion criminal) to settle a series of False Claims Act cases brought to the U.S. Government by whistleblowers. GSK was charged with illegally promoting nine different prescription drugs, including the antidepressants Wellbutrin and Paxil, the diabetes medication Avandia, the pulmonary drug Advair, and the anti-nausea medication Zofran, as well as five other drugs: Imitrex, Lamictal, Lotronex, Floven, and Valtrex. GSK was charged with pervasive illegal conduct that continued for more than a decade, including paying kickbacks, doctoring and fabricating scientific research and articles, bribing doctors with vacations to Hawaii and Puerto Rico, and creating marketing kits packed with unsubstantiated claims.  

Johnson & Johnson:

Johnson & Johnson paid $2.2 billion to resolve criminal and civil liability arising from allegations relating to kickbacks and off-label marketing of the drugs Risperdal, Invega and Natrecor. Risperdal’s illegal sales practices began when the drug was off-label marketed by its Janssen subsidiary, whose vice president of sales, Alex Gorsky, is now CEO of Johnson & Johnson.  The global resolution is one of the largest health care fraud settlements in U.S. history, including criminal fines and forfeiture totaling $485 million and civil settlements with the federal government and states totaling $1.72 billion.


Pfizer paid a total of $2.3 billion, of which $1.3 billion was a criminal fine for kickbacks and off-label marketing and $1 billion was paid under the False Claims Act. The drugs involved were Bextra (an anti-inflammatory drug), Geodon (an anti-psychotic drug), Lipitor (a cholesterol drug), Norvasc (anti-hypertensive drug), Viagra (erectile dysfunction), Zithromax (antibiotic), Zyrtec (antihistamine), Zyvox (an antibiotic), Lyrica (an anti-epileptic drug), Relpax (anti-migraine drug), Celebrex (anti-inflammatory drug), and Depo-provera (birth control).

Bank of America:

Bank of America and its former and current subsidiaries, including Countrywide Financial Corporation and Merrill Lynch will pay $16.65 billion– the largest civil settlement with a single entity in American history ­— to resolve federal and state claims. The settlement relates to the packaging, marketing, sale, arrangement, structuring and issuance of RMBS, collateralized debt obligations (CDOs), and the bank’s practices concerning the underwriting and origination of mortgage loans. The investigation into these practices were in part brought by three private whistleblower lawsuits filed under seal pursuant to the False Claims Act. As part of the settlement, Bank of America and Countrywide have agreed to pay $1 billion to resolve their liability under the False Claims Act.


In July 2006, Tenet Healthcare (formerly known as NME) agreed to pay the Federal Government $900 million for billing violations that include manipulation of outlier payments to Medicare, as well as kickbacks, upcoding, and bill padding.  The DoJ press release notes that the settlement was based on the company's ability to pay; a nice way of saying that Tenet stole more money than was recovered in this settlement.


Abbott Laboratories paid over $1.5 billion to settle civil and criminal charges in part brought by four False Claims Act qui tam cases alleging the company promoted the off-label use of Depakote, an anti-seizure drug.  The settlement, includes a $700 million criminal fine and an $800 million civil settlement (covered under the False Claims Act cases) with the federal government  ($560,851,357) and the states ($239,148,643) that chose to participate. 


In December 2000, The Healthcare Company (HCA) pled guilty to criminal conduct and agreed to pay more than $840 million in criminal fines, civil penalties and damages for unlawful billing practices. $731,400,000 was recovered under the False Claims Act.  The settlement resolved allegations that the company knowingly ordered lab tests that were not medically necessary, "upcoding" medical problems in order to get higher reimbursements, billing the government for advertising under the guise of "community education," and billing the government for non-reimbursable costs incurred in the purchase of home health agencies. 


In January 2008, Merck settled the very first nominal pricing fraud case where the company was accused of taking kickback and violating Medicaid best price regulations for Vioxx (an arthritis drug), Zocor (a cholesterol drug), Pepcid (an acid-reflux drug), Cozaar (a hypertensive medication), Fosamax (a bone loss drug) Maxalt (a migraine medication) and Singulair (an asthma medication).


This settlement resolves HCA's civil liability for false claims including cost report fraud and the payment of kickbacks to physicians. In a separate administrative settlement with the Centers for Medicare & Medicaid Services (CMS), HCA agreed to pay an additional $250 million to resolve overpayment claims arising from its cost reporting practices. Combined with the December 2000 settlement, the government has recovered $1.7 billion from HCA, by far the largest recovery ever reached by the government in a health care fraud investigation.


Merck paid $628 million to resolve allegations that its representatives made inaccurate and misleading statements about the drug Vioxx's cardiovascular safety in order to increase sales. Merck also made false statements to state Medicaid agencies about the cardiovascular safety of Vioxx, and that those agencies relied on Merck's false claims in making payment decisions about the drug. In addition to the civil penalty, Merck was found guilty of criminal charges that resulted in a $950 million total penalty. 

JPMorgan Chase:

JP Morgan Chase paid $614 Million to settle allegations that they knowingly provided noncompliant Federal Housing Authority and Veterans Affairs insured loans for over a decade, beginning in 2002. In addition to issuing the noncompliant loans, JP Morgan Chase failed to disclose the results of an internal investigation that concluded they had issued hundreds of loans that should not have been insured by FHA or the VA. When unqualified loans defaulted, the FHA and VA had to cover the losses, even though JP Morgan Chase falsely approved them in the first place.